L. Chen, D. J. Magliano, and P. Z. Zimmet, The worldwide epidemiology of type 2 diabetes 324 mellitus--present and future perspectives, Nat Rev Endocrinol, vol.8, issue.4, pp.228-264, 2011.

D. R. Whiting, L. Guariguata, C. Weil, and J. Shaw, Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies 328 with 4.4 million participants, Diabetes Res Clin Pract, vol.94, issue.3, pp.1513-1530, 2011.

P. Zhang, X. Zhang, J. Brown, D. Vistisen, R. Sicree et al., Global 330 healthcare expenditure on diabetes for 2010 and 2030, Diabetes Res Clin Pract, vol.87, issue.3, pp.293-331, 2010.

S. Saha, U. G. Gerdtham, and P. Johansson, Economic evaluation of lifestyle interventions for 333 preventing diabetes and cardiovascular diseases, Int J Environ Res Public Health, vol.7, issue.8, pp.3150-95, 2010.

K. Backholer, A. Peeters, W. H. Herman, J. E. Shaw, D. Liew et al., 335 Diabetes prevention and treatment strategies: are we doing enough? Diabetes Care, vol.36, pp.2714-2723, 2013.

J. P. Ferreira, N. Girerd, E. Bozec, L. Merckle, A. Pizard et al., , p.338

J. L. Machu and J. M. Boivin, Cohort Profile: Rationale and design of the fourth visit of the 339 STANISLAS cohort: a familial longitudinal population-based cohort from the Nancy region of France

, Int J Epidemiol, vol.47, issue.2, pp.395-395, 2018.

C. Xhaard, C. Dandine-roulland, P. Villemereuil, E. L. Floch, D. Bacq-daian et al., , vol.342

J. P. Ferreira, J. F. Deleuze, and F. Zannad, Heritability of a resting heart rate in a 20-year follow-343 up family cohort with GWAS data: Insights from the STANISLAS cohort, Eur J Prev Cardiol, p.344, 2019.

, Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019

, Diabetes Care, vol.42, p.10, 2019.

M. Lundberg, A. Eriksson, B. Tran, E. Assarsson, and S. Fredriksson, Homogeneous antibody-348 based proximity extension assays provide sensitive and specific detection of low-abundant proteins 349 in human blood, Nucleic Acids Res, vol.39, issue.15, p.11, 2011.

P. Pellicori, J. P. Ferreira, B. Mariottoni, H. P. Brunner-la-rocca, and F. Z. Ahmed, , vol.351

J. Verdonschot, T. Collier, J. J. Cuthbert, J. Petutschnigg, and B. Mujaj, Effects of 352 spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: 353 rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, 354 prevention trial. The Heart OMics in AGing (HOMAGE) trial, Eur J Heart Fail, vol.355, p.12, 2020.

S. Kohler, L. Carmody, N. Vasilevsky, J. O. Jacobsen, D. Danis et al., , vol.356

M. Gargano, N. L. Harris, N. Matentzoglu, J. A. Mcmurry, and D. Osumi-sutherland, Expansion 357 of the Human Phenotype Ontology (HPO) knowledge base and resources, Nucleic Acids Res, vol.47, issue.D1, p.13, 2019.

J. Pinero, A. Bravo, N. Queralt-rosinach, A. Gutierrez-sacristan, J. Deu-pons et al., DisGeNET: a comprehensive platform integrating 361 information on human disease-associated genes and variants, Nucleic Acids Res, vol.45, issue.D1, p.14, 2017.

M. Franco, U. Bilal, P. Ordunez, M. Benet, A. Morejon et al., , vol.364

R. S. Cooper, Population-wide weight loss and regain in relation to diabetes burden and 365 cardiovascular mortality in Cuba 1980-2010: repeated cross sectional surveys and ecological 366 comparison of secular trends, Bmj, vol.346, p.15, 2013.

L. J. Maple-brown, A. K. Sinha, and E. A. Davis, Type 2 diabetes in indigenous Australian 368 children and adolescents, J Paediatr Child Health, vol.46, issue.9, p.16, 2010.

C. Jefferies, P. Carter, P. W. Reed, W. Cutfield, F. Mouat et al., The 370 incidence, clinical features, and treatment of type 2 diabetes in children <15 yr in a population-based 371 cohort from Auckland, Pediatr Diabetes, vol.13, issue.4, p.17, 1995.

P. Zimmet, K. G. Alberti, and J. Shaw, Global and societal implications of the diabetes 373 epidemic, Nature, vol.414, issue.6865, p.18, 2001.

S. M. Haffner, M. P. Stern, H. P. Hazuda, B. D. Mitchell, and J. K. Patterson, Cardiovascular 375 risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start 376 ticking before the onset of clinical diabetes?, Jama, vol.263, issue.21, p.19, 1990.

R. Kahn and M. B. Davidson, The reality of type 2 diabetes prevention. Diabetes Care, Prev Med, vol.37, issue.4, p.21, 2014.

W. C. Knowler, S. E. Fowler, R. F. Hamman, C. A. Christophi, and H. J. Hoffman, , p.381

A. T. Brown-friday, J. O. Goldberg, R. Venditti, E. Nathan, and D. M. , 10-year follow-up of diabetes 382 incidence and weight loss in the Diabetes Prevention Program Outcomes Study, Lancet, vol.374, issue.9702, p.22, 2009.

W. C. Knowler, E. Barrett-connor, S. E. Fowler, R. F. Hamman, J. M. Lachin et al.,

A. Nathan and D. M. , Reduction in the incidence of type 2 diabetes with lifestyle intervention or 386 metformin, N Engl J Med, vol.346, issue.6, p.23, 2002.

R. F. Hamman, R. R. Wing, S. L. Edelstein, J. M. Lachin, G. A. Bray et al., , vol.388

M. Hoskin, A. M. Kriska, E. J. Mayer-davis, and X. Pi-sunyer, Effect of weight loss with lifestyle 389 intervention on risk of diabetes, Diabetes Care, vol.29, issue.9, p.24, 2006.

J. Lindstrom, P. Ilanne-parikka, M. Peltonen, S. Aunola, J. G. Eriksson et al., , vol.391

H. Hamalainen, P. Harkonen, S. Keinanen-kiukaanniemi, and M. Laakso, The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes 395 prevention: an intent-to-treat analysis of the DPP/DPPOS, Diabetes Care, vol.368, issue.9548, p.26, 2006.

R. Hjortebjerg, IGFBP-4 and PAPP-A in normal physiology and disease, Growth Horm IGF Res, vol.397, p.27, 2018.

J. I. Jones and D. R. Clemmons, Insulin-like growth factors and their binding proteins: biological 399 actions, Endocr Rev, vol.16, issue.1, p.28, 1995.

C. A. Conover, M. A. Mason, L. K. Bale, S. C. Harrington, M. Nyegaard et al., , p.401

M. T. Overgaard, Transgenic overexpression of pregnancy-associated plasma protein-A in murine 402 arterial smooth muscle accelerates atherosclerotic lesion development, Am J Physiol Heart Circ 403 Physiol, vol.299, issue.2, p.29, 2010.

S. Mazerbourg, M. T. Overgaard, C. Oxvig, M. Christiansen, C. A. Conover et al., , p.405

I. Vidaud, M. Tosser-klopp, G. Zapf, J. Monget, and P. , Pregnancy-associated plasma protein-A (PAPP-406 A) in ovine, bovine, porcine, and equine ovarian follicles: involvement in IGF binding protein-4 407 proteolytic degradation and mRNA expression during follicular development, Endocrinology, vol.408, issue.12, p.30, 2001.

D. Byun, S. Mohan, M. Yoo, C. Sexton, D. J. Baylink et al., Pregnancy-associated 410 plasma protein-A accounts for the insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) 411 proteolytic activity in human pregnancy serum and enhances the mitogenic activity of IGF by 412 degrading IGFBP-4 in vitro, J Clin Endocrinol Metab, vol.86, issue.2, p.31, 2001.

J. L. Beaudeux, L. Burc, F. Imbert-bismut, P. Giral, M. Bernard et al., , p.414

M. J. , Serum plasma pregnancy-associated protein A: a potential marker of echogenic carotid 415 atherosclerotic plaques in asymptomatic hyperlipidemic subjects at high cardiovascular risk

, Arterioscler Thromb Vasc Biol, vol.23, issue.1, p.32, 2003.

G. Panagiotou, A. D. Anastasilakis, G. Kynigopoulos, E. C. Skouvaklidou, and Z. G. Saridakis, , vol.418

J. Upadhyay, E. Pagkalidou, A. Apostolou, T. Karagiozoglou-lampoudi, and C. S. Mantzoros, 419 Physiological parameters regulating circulating levels of the IGFBP-4/Stanniocalcin-2/PAPP-A axis, vol.75, pp.16-24, 2017.

R. Hjortebjerg, E. Laugesen, P. Hoyem, C. Oxvig, B. Stausbol-gron et al., , p.422

W. Y. Poulsen, P. L. Hansen, and T. K. , The IGF system in patients with type 2 diabetes: 423 associations with markers of cardiovascular target organ damage, Eur J Endocrinol, vol.176, issue.5, p.34, 2017.

S. Pellitero, J. L. Reverter, E. Pizarro, M. C. Pastor, M. L. Granada et al., , p.426

J. C. Salinas, I. Sanmarti, and A. , Pregnancy-associated plasma protein-a levels are related to glycemic 427 control but not to lipid profile or hemostatic parameters in type 2 diabetes. Diabetes Care, vol.30, p.35, 2007.

Y. Aso, K. Okumura, S. Wakabayashi, K. Takebayashi, S. Taki et al., Elevated 430 pregnancy-associated plasma protein-a in sera from type 2 diabetic patients with 431 hypercholesterolemia: associations with carotid atherosclerosis and toe-brachial index, J Clin, p.432

E. Metab, , vol.89, p.36, 2004.

J. R. Mader, Z. T. Resch, G. R. Mclean, J. H. Mikkelsen, C. Oxvig et al., , p.434

C. A. , Mice deficient in PAPP-A show resistance to the development of diabetic nephropathy, J 435 Endocrinol, vol.219, issue.1, p.37, 2013.

C. A. Conover, L. K. Bale, J. R. Mader, M. A. Mason, K. P. Keenan et al., Longevity 437 and age-related pathology of mice deficient in pregnancy-associated plasma protein-A, Biol Sci Med Sci, vol.438, issue.6, p.38, 2010.

R. K. Junnila, E. O. List, D. E. Berryman, J. W. Murrey, and J. J. Kopchick, The GH/IGF-1 axis in 440 ageing and longevity, Nat Rev Endocrinol, vol.2013, issue.6, p.39

A. N. Silahtaroglu, Z. Tumer, T. Kristensen, L. Sottrup-jensen, and N. Tommerup, Assignment 442 of the human gene for pregnancy-associated plasma protein A (PAPPA) to 9q33.1 by fluorescence in 443 situ hybridization to mitotic and meiotic chromosomes, Cytogenet Cell Genet, vol.62, issue.4, p.40, 1993.

V. Sagar, R. Vatapalli, B. Lysy, S. Pamarthy, J. F. Anker et al., , p.445

K. Stadler and W. M. , EPHB4 inhibition activates ER stress to promote immunogenic cell death of 446 prostate cancer cells, Cell Death Dis, vol.10, issue.11, p.41, 2019.

M. A. Ruby, J. Massart, D. M. Hunerdosse, M. Schonke, J. C. Correia et al., , p.448

J. L. Ruas, E. Naslund, D. K. Nomura, and J. R. Zierath, Human Carboxylesterase, vol.2, p.449

, Induced Diacylglycerol Accumulation and Glucose Intolerance, Cell Rep, vol.18, issue.3, p.42, 2017.

C. F. Ware, The TNF Superfamily-2008, Cytokine Growth Factor Rev, vol.19, issue.3-4, p.43, 2008.

D. H. Kong, Y. K. Kim, M. R. Kim, J. H. Jang, and S. Lee, Emerging Roles of Vascular Cell 452

, Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer, Int J Mol Sci, vol.19, issue.4, p.44, 2018.

L. D. Bondurant, M. Ameka, M. C. Naber, K. R. Markan, S. O. Idiga et al., , p.454

S. A. Walsh, D. M. Ornitz, and M. J. Potthoff, FGF21 Regulates Metabolism Through Adipose-455 Dependent and -Independent Mechanisms, Cell Metab, vol.25, issue.4, p.45, 2017.

Y. S. Wang, J. Ye, Y. H. Cao, R. Zhang, Y. Liu et al., Increased 457 serum/plasma fibroblast growth factor 21 in type 2 diabetes mellitus: a systematic review and meta-458 analysis, Postgrad Med J, vol.2019, p.46, 1121.

G. R. Davis, T. Deville, J. Guillory, D. Bellar, and A. G. Nelson, Relationship between family 460 history of type 2 diabetes and serum FGF21, Eur J Clin Invest, vol.47, issue.11, pp.853-859, 2017.